Juraj Dobiáš

A development of chimeric VEGFR2 TK inhibitor based on two ligand conformers from PDB: 1Y6A complex – Medicinal chemistry consequences of a TKs analysis

Lucia Lintnerová, Melissa García‐Caballero, Fridrich Gregáň et al. · European Journal of Medicinal Chemistry · 2013 · 42 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Biochemistry +11

Novel CLK1 inhibitors based on N-aryloxazol-2-amine skeleton - A possible way to dual VEGFR2 TK/CLK ligands

Miroslav Murár, Juraj Dobiáš, Peter Šramel et al. · European Journal of Medicinal Chemistry · 2016 · 24 citations · Full text

Medicinal Chemistry, Medicine, Receptor Tyrosine Kinase +11

ANTIPROTOZOAL ANTIBIOTICS. II. ISOLATION AND CHARACTERIZATION OF TRYPACIDIN, A NEW ANTIBIOTIC, ACTIVE AGAINST TRYPANOSOMA CRUZI AND TOXOPLASMA GONDII.

J. Balán, L. Ebringer, Pavel Němec et al. · PubMed · 1963 · 20 citations

A New Antibiotic, Antibiotics, Antiparasitic Agent +10

Giant mitochondria in chloroplast-deprivedEuglena gracilis late after N-succinimidylofloxacin treatment

J Polónyi, L. Ebringer, Juraj Dobiáš et al. · Folia Microbiologica · 1998 · 17 citations

Biology, Bioorganic Chemistry, Mitochondrial Function +7

Synergic activity of selenium and probiotic bacteriumEnterococcus faecium M-74 against selected mutagens inSalmonella assay

Anna Belicova, L. Križková, Juraj Dobiáš et al. · Folia Microbiologica · 2004 · 15 citations

Mutagens Insalmonella, Probiotic, Antimicrobial Susceptibility +8